Show simple item record

Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1.

dc.contributor.authorTyndall, MW
dc.contributor.authorPlourde, PJ
dc.contributor.authorAgoki, E
dc.contributor.authorMalisa, W
dc.contributor.authorNdinya-Achola, JO
dc.contributor.authorPlummer, FA
dc.contributor.authorRonald, AR
dc.date.accessioned2013-04-26T09:02:37Z
dc.date.available2013-04-26T09:02:37Z
dc.date.issued1993
dc.identifier.citationAm J Med. 1993 Mar 22;94(3A):85S-88Sen
dc.identifier.urihttp://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/8452188
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16981
dc.description.abstractFleroxacin was prescribed to treat both HIV-negative and HIV-positive men with proven chancroid in an open study. HIV-negative men were treated with a single 400-mg dose of fleroxacin, and HIV-positive men were treated with 400 mg daily for 5 days. Three of the 58 evaluable HIV-negative men were clinical and microbiologic failures, and two of the 22 evaluable HIV-positive men had persisting infection with Haemophilus ducreyi. Both regimens were well tolerated. Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in menen
dc.language.isoenen
dc.titleFleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1.en
dc.typeArticleen
local.publisherWHO Collaborating Centre for Research and Training in Sexually Transmitted Diseasesen
local.publisherUniversity of Nairobi, Kenyaen


Files in this item

Thumbnail
Name:
Abstract.pdf
Size:
80.55Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record